Real-time Estimate
Cboe BZX
12:35:58 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
67.61
USD
|
+0.10%
|
|
+0.25%
|
+8.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
940.7
|
1,987
|
2,593
|
3,097
|
3,153
|
3,446
|
-
|
-
|
Enterprise Value (EV)
1 |
777.4
|
1,767
|
2,372
|
2,740
|
2,808
|
3,117
|
3,075
|
2,994
|
P/E ratio
|
-9.9
x
|
-33.7
x
|
-30.1
x
|
-48.9
x
|
-519
x
|
-699
x
|
96.3
x
|
62.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
68.1
x
|
17.8
x
|
14.4
x
|
11.3
x
|
8.61
x
|
7.71
x
|
6.42
x
|
5.45
x
|
EV / Revenue
|
56.2
x
|
15.8
x
|
13.2
x
|
10
x
|
7.66
x
|
6.98
x
|
5.73
x
|
4.74
x
|
EV / EBITDA
|
-9.79
x
|
-34
x
|
-40.7
x
|
-51.5
x
|
-207
x
|
179
x
|
55.1
x
|
66.7
x
|
EV / FCF
|
-9.17
x
|
-20.4
x
|
-
|
2,830
x
|
-
|
59.1
x
|
32.8
x
|
-
|
FCF Yield
|
-10.9%
|
-4.9%
|
-
|
0.04%
|
-
|
1.69%
|
3.05%
|
-
|
Price to Book
|
5.16
x
|
6.42
x
|
5.38
x
|
5.43
x
|
4.96
x
|
5.25
x
|
4.75
x
|
4.16
x
|
Nbr of stocks (in thousands)
|
33,948
|
39,809
|
46,297
|
49,530
|
50,662
|
51,018
|
-
|
-
|
Reference price
2 |
27.71
|
49.92
|
56.00
|
62.53
|
62.23
|
67.54
|
67.54
|
67.54
|
Announcement Date
|
3/4/20
|
2/25/21
|
2/24/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.82
|
111.5
|
180.3
|
273.7
|
366.4
|
446.7
|
536.6
|
631.8
|
EBITDA
1 |
-79.41
|
-52.02
|
-58.27
|
-53.22
|
-13.57
|
17.43
|
55.81
|
44.91
|
EBIT
1 |
-80.6
|
-53.76
|
-67.39
|
-64.95
|
-26.06
|
-10.66
|
28.97
|
45.52
|
Operating Margin
|
-583.21%
|
-48.2%
|
-37.38%
|
-23.73%
|
-7.11%
|
-2.39%
|
5.4%
|
7.2%
|
Earnings before Tax (EBT)
1 |
-79.93
|
-54.91
|
-79.28
|
-62.32
|
-8.744
|
4.443
|
42.42
|
57.66
|
Net income
1 |
-79.93
|
-54.92
|
-80.07
|
-59.7
|
-6.088
|
-4.895
|
36.14
|
56.05
|
Net margin
|
-578.39%
|
-49.24%
|
-44.41%
|
-21.81%
|
-1.66%
|
-1.1%
|
6.73%
|
8.87%
|
EPS
2 |
-2.800
|
-1.480
|
-1.860
|
-1.280
|
-0.1200
|
-0.0967
|
0.7011
|
1.088
|
Free Cash Flow
1 |
-84.79
|
-86.68
|
-
|
0.968
|
-
|
52.7
|
93.9
|
-
|
FCF margin
|
-613.55%
|
-77.72%
|
-
|
0.35%
|
-
|
11.8%
|
17.5%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
302.34%
|
168.25%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
259.86%
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
2/25/21
|
2/24/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
53.14
|
48.42
|
68.98
|
70.38
|
85.92
|
70.65
|
92.89
|
93.1
|
109.7
|
91.41
|
112.7
|
113.7
|
130.4
|
110.9
|
136.2
|
EBITDA
1 |
-15.04
|
-20.5
|
-18.54
|
-13.45
|
-0.729
|
-11.55
|
-8.842
|
2.567
|
4.258
|
-16
|
2.1
|
2.4
|
5.4
|
-
|
-
|
EBIT
1 |
-17.68
|
-23.53
|
-21.43
|
-16.38
|
-3.609
|
-14.37
|
-12.07
|
-0.687
|
1.066
|
-19.18
|
2.077
|
2.502
|
7.051
|
-4.55
|
7
|
Operating Margin
|
-33.27%
|
-48.6%
|
-31.07%
|
-23.27%
|
-4.2%
|
-20.33%
|
-12.99%
|
-0.74%
|
0.97%
|
-20.98%
|
1.84%
|
2.2%
|
5.41%
|
-4.1%
|
5.14%
|
Earnings before Tax (EBT)
1 |
-17.65
|
-23.78
|
-21.91
|
-16.77
|
0.143
|
-10.06
|
-7.646
|
3.501
|
5.456
|
-15.26
|
5.2
|
5.92
|
9.86
|
-0.15
|
11.45
|
Net income
1 |
-15.17
|
-22.67
|
-21.44
|
-16.25
|
0.665
|
-9.248
|
-7.342
|
3.928
|
6.574
|
-19.11
|
5.45
|
5.329
|
8.65
|
-3.408
|
10.26
|
Net margin
|
-28.54%
|
-46.82%
|
-31.09%
|
-23.09%
|
0.77%
|
-13.09%
|
-7.9%
|
4.22%
|
5.99%
|
-20.91%
|
4.83%
|
4.69%
|
6.63%
|
-3.07%
|
7.53%
|
EPS
2 |
-0.3400
|
-0.5000
|
-0.4700
|
-0.3400
|
0.0100
|
-0.1900
|
-0.1500
|
0.0800
|
0.1300
|
-0.3800
|
0.0775
|
0.0888
|
0.1543
|
-0.0517
|
0.1800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/1/22
|
10/31/22
|
3/1/23
|
5/1/23
|
7/27/23
|
10/30/23
|
2/28/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
163
|
220
|
221
|
357
|
345
|
329
|
370
|
451
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.8
|
-86.7
|
-
|
0.97
|
-
|
52.7
|
93.9
|
-
|
ROE (net income / shareholders' equity)
|
-49%
|
-23.3%
|
-20.8%
|
-11.3%
|
-1.01%
|
-3.49%
|
2.98%
|
6.68%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.370
|
7.770
|
10.40
|
11.50
|
12.60
|
12.90
|
14.20
|
16.20
|
Cash Flow per Share
2 |
-2.920
|
-2.260
|
-
|
0.0700
|
-0.0400
|
1.320
|
-
|
-
|
Capex
|
1.34
|
2.94
|
-
|
2.22
|
3.55
|
-
|
-
|
-
|
Capex / Sales
|
9.69%
|
2.63%
|
-
|
0.81%
|
0.97%
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
2/25/21
|
2/24/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
67.54
USD Average target price
71.8
USD Spread / Average Target +6.31% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.53% | 3.45B | | +10.11% | 126B | | -5.15% | 11.33B | | +6.07% | 9.27B | | +37.46% | 5.5B | | -8.69% | 2.81B | | -6.38% | 2.08B | | -10.91% | 2.09B | | -23.21% | 1.78B | | -9.29% | 1.14B |
Medical Devices & Implants
|